OTCMKTS:ZLDPF Zealand Pharma A/S - ZLDPF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. $30.13 -0.44 (-1.44%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$30.02▼$30.1350-Day Range$25.46▼$30.5752-Week Range$11.14▼$30.57Volume650 shsAverage Volume83 shsMarket Capitalization$1.55 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest About Zealand Pharma A/S (OTCMKTS:ZLDPF) StockZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLDPF Stock News HeadlinesFebruary 2, 2023 | msn.comZorb New Zealand At The World's Largest Ball Rolling ParkFebruary 1, 2023 | msn.comNew Zealand announces NZ$700,000 in additional flood support as cleanup beginsFebruary 3, 2023 | PressReach (Ad)Biotech Stock AlertRead Small Pharma's depression clinical trial results.December 30, 2022 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at December 30, 2022November 30, 2022 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at November 30, 2022November 12, 2022 | seekingalpha.comZLDPF Zealand Pharma A/SNovember 1, 2022 | finance.yahoo.comZealand Pharma Announces Presentations at The Obesity Society Annual MeetingOctober 11, 2022 | finance.yahoo.comZealand Pharma major shareholder announcement: Polar CapitalFebruary 3, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.October 10, 2022 | finance.yahoo.comZealand Pharma major shareholder announcement: Van Herk InvestmentsOctober 4, 2022 | finance.yahoo.comZealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 millionOctober 4, 2022 | finance.yahoo.comZealand Pharma announces directed issue and private placement of approximately 4.5m new sharesSeptember 19, 2022 | finance.yahoo.comZealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE MeetingSeptember 13, 2022 | finance.yahoo.comZealand Pharma grants warrants to employees in DenmarkSeptember 7, 2022 | finance.yahoo.comZealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)August 31, 2022 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at August 31, 2022August 24, 2022 | finance.yahoo.comZealand Pharma Appoints Henriette Wennicke as Chief Financial OfficerAugust 13, 2022 | msn.comNew Zealand central bank to carry on with 50bps hike in August: Reuters pollAugust 12, 2022 | msn.comNew Zealand rescuers use buckets and towels in race to save stranded dolphinsAugust 11, 2022 | nasdaq.comPOLL-New Zealand central bank to carry on with 50bps hike in AugustAugust 11, 2022 | msn.comNew Zeland's Fonterra says high-quality FTAs boost confidence to keep investing in MalaysiaAugust 9, 2022 | msn.comPfizer's Perth employees strike over payAugust 8, 2022 | msn.comAustralia’s Richest Postcode has Been Revealed and it’s NOT in Sydney or MelbourneAugust 8, 2022 | benzinga.comZealand Pharma (OTC:ZLDPF), Analyst Ratings, Price Targets, PredictionsAugust 8, 2022 | msn.comSeveral Auckland stores targeted by thieves overnightAugust 8, 2022 | msn.comNew Zealand newspapers call for Foster's axing as resentment swellsAugust 7, 2022 | msn.comEliminating HIV is within our graspSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLDPF Company Calendar Last Earnings11/10/2022Today2/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CUSIPN/A CIKN/A Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees355Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,990,000.00 Net Margins-810.58% Pretax Margin-739.28% Return on Equity-162.39% Return on Assets-65.49% Debt Debt-to-Equity Ratio1.01 Current Ratio3.69 Quick Ratio3.69 Sales & Book Value Annual Sales$46.54 million Price / Sales33.35 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares51,510,000Free FloatN/AMarket Cap$1.55 billion OptionableNot Optionable Beta0.68 Key ExecutivesMr. Adam Sinding Steensberg M.D. (Age 49)Pres & CEO Comp: $733.86kMs. Henriette WennickeChief Financial OfficerMr. Ivan Mourits Moller (Age 51)Chief Operating Officer Lani Pollworth MorvanInvestor Relations & Communications OfficerMr. Mads KronborgHead of Investor Relations & CommunicationMr. Ravinder ChahilSr. VP & Gen. CounselMs. Christina Sonnenborg Bredal (Age 38)Sr. VP and Global Head of People & Organization Ms. Hanne Heidenheim Bak (Age 70)Sr. Project Director, R&D Operations Mang. and Employee Representative Director Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular PharmacologyDr. Danilo VergeHead of Global Medical AffairsMore ExecutivesKey CompetitorsPharma MarOTCMKTS:PHMMFClinigen GroupOTCMKTS:CLIGFAurora CannabisOTCMKTS:ACBFFNihon KohdenOTCMKTS:NHNKYOxford BiomedicaOTCMKTS:OXBDFView All Competitors ZLDPF Stock - Frequently Asked Questions Should I buy or sell Zealand Pharma A/S stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZLDPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZLDPF, but not buy additional shares or sell existing shares. View ZLDPF analyst ratings or view top-rated stocks. How have ZLDPF shares performed in 2023? Zealand Pharma A/S's stock was trading at $28.18 at the beginning of the year. Since then, ZLDPF stock has increased by 6.9% and is now trading at $30.13. View the best growth stocks for 2023 here. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its quarterly earnings data on Thursday, November, 10th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.23. The firm earned $5.92 million during the quarter, compared to analyst estimates of $5.30 million. Zealand Pharma A/S had a negative net margin of 810.58% and a negative trailing twelve-month return on equity of 162.39%. What is Zealand Pharma A/S's stock symbol? Zealand Pharma A/S trades on the OTCMKTS under the ticker symbol "ZLDPF." How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zealand Pharma A/S's stock price today? One share of ZLDPF stock can currently be purchased for approximately $30.13. How much money does Zealand Pharma A/S make? Zealand Pharma A/S (OTCMKTS:ZLDPF) has a market capitalization of $1.55 billion and generates $46.54 million in revenue each year. The company earns $-161,990,000.00 in net income (profit) each year or ($3.79) on an earnings per share basis. How many employees does Zealand Pharma A/S have? The company employs 355 workers across the globe. How can I contact Zealand Pharma A/S? Zealand Pharma A/S's mailing address is Sydmarken 11 Soborg, Copenhagen G7, 2860. The official website for the company is www.zealandpharma.com. The company can be reached via phone at 45-8877-3600, via email at investors@zealandpharma.com, or via fax at 45-8877-3898. This page (OTCMKTS:ZLDPF) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.